EXOC3

Summary

EXOC3 (exocyst complex component 3, HGNC:30378) is a protein-coding gene on chromosome 5p15.33, encoding Exocyst complex component 3 (O60645). Component of the exocyst complex involved in the docking of exocytic vesicles with fusion sites on the plasma membrane. It is a selective cancer dependency (DepMap: 74.5% of cell lines).

The protein encoded by this gene is a component of the exocyst complex, a multiple protein complex essential for targeting exocytic vesicles to specific docking sites on the plasma membrane. Though best characterized in yeast, the component proteins and functions of exocyst complex have been demonstrated to be highly conserved in higher eukaryotes. At least eight components of the exocyst complex, including this protein, are found to interact with the actin cytoskeletal remodeling and vesicle transport machinery. The complex is also essential for the biogenesis of epithelial cell surface polarity.

Source: NCBI Gene 11336 — RefSeq curated summary.

At a glance

• GWAS associations: 7
• Clinical variants (ClinVar): 128 total
• Druggable target: yes
• Cancer dependency (DepMap): dependent in 74.5% of screened cell lines
• MANE Select transcript: NM_007277

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30378
Approved symbol	EXOC3
Name	exocyst complex component 3
Location	5p15.33
Locus type	gene with protein product
Status	Approved
Aliases	Sec6
Ensembl gene	ENSG00000180104
Ensembl biotype	protein_coding
OMIM	608186
Entrez	11336

Gene structure

Transcript identifiers

Ensembl transcripts: 17 — 10 protein_coding, 3 retained_intron, 2 nonsense_mediated_decay, 2 protein_coding_CDS_not_defined

ENST00000315013, ENST00000503889, ENST00000505947, ENST00000508022, ENST00000509294, ENST00000510028, ENST00000510441, ENST00000511015, ENST00000512944, ENST00000515601, ENST00000866265, ENST00000866266, ENST00000929778, ENST00000929779, ENST00000929780, ENST00000929781, ENST00000941759

RefSeq mRNA: 1 — MANE Select: NM_007277 NM_007277

CCDS: CCDS54830

Canonical transcript exons

ENST00000512944 — 13 exons

Exon	Start	End
ENSE00001273313	465111	465272
ENSE00001273317	464290	464412
ENSE00001273327	461960	462070
ENSE00001273331	459359	459459
ENSE00001273338	457900	458025
ENSE00001273345	456889	457006
ENSE00001273352	453370	454051
ENSE00001273358	447533	447752
ENSE00002029435	466727	467290
ENSE00002036650	443176	443290
ENSE00003536012	462157	462307
ENSE00003598581	446150	446349
ENSE00003665455	465718	465845

Expression profiles

Bgee: expression breadth ubiquitous, 288 present calls, max score 96.78.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.8048 / max 130.7590, expressed in 1805 samples.

FANTOM5 promoters (6 alternative TSS)

Promoter ID	TPM avg	Samples expressed
55481	14.8332	1797
55480	1.4498	945
55482	0.2202	44
55485	0.2201	82
55487	0.0689	12
55490	0.0126	5

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of transverse colon	UBERON:0004991	96.78	gold quality
adenohypophysis	UBERON:0002196	96.66	gold quality
sural nerve	UBERON:0015488	96.35	gold quality
mucosa of stomach	UBERON:0001199	96.31	gold quality
right uterine tube	UBERON:0001302	96.29	gold quality
metanephros cortex	UBERON:0010533	96.06	gold quality
skin of leg	UBERON:0001511	95.89	gold quality
pituitary gland	UBERON:0000007	95.88	gold quality
body of stomach	UBERON:0001161	95.80	gold quality
skin of abdomen	UBERON:0001416	95.80	gold quality
transverse colon	UBERON:0001157	95.52	gold quality
small intestine Peyer’s patch	UBERON:0003454	95.34	gold quality
left testis	UBERON:0004533	95.26	gold quality
muscle layer of sigmoid colon	UBERON:0035805	95.02	gold quality
hindlimb stylopod muscle	UBERON:0004252	94.94	gold quality
lower esophagus muscularis layer	UBERON:0035833	94.78	gold quality
lower esophagus	UBERON:0013473	94.77	gold quality
right testis	UBERON:0004534	94.74	gold quality
left lobe of thyroid gland	UBERON:0001120	94.73	gold quality
esophagus mucosa	UBERON:0002469	94.71	gold quality
gastrocnemius	UBERON:0001388	94.68	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	94.66	gold quality
popliteal artery	UBERON:0002250	94.64	gold quality
tibial artery	UBERON:0007610	94.64	gold quality
esophagus	UBERON:0001043	94.57	gold quality
gall bladder	UBERON:0002110	94.45	gold quality
lower esophagus mucosa	UBERON:0035834	94.42	gold quality
minor salivary gland	UBERON:0001830	94.41	gold quality
fundus of stomach	UBERON:0001160	94.35	gold quality
right lobe of thyroid gland	UBERON:0001119	94.33	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.35

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

19 targeting EXOC3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4493	99.90	66.48	977
HSA-MIR-1207-5P	99.49	69.11	2983
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-6871-3P	99.43	68.85	741
HSA-MIR-324-3P	99.26	66.31	1034
HSA-MIR-4763-3P	99.10	67.83	2649
HSA-MIR-4270	99.02	66.26	1987
HSA-MIR-1301-3P	98.64	68.27	1071
HSA-MIR-5047	98.64	68.62	1035
HSA-MIR-6792-5P	98.39	68.16	1330
HSA-MIR-4664-5P	98.17	65.07	1020
HSA-MIR-4772-3P	98.04	65.60	1203
HSA-MIR-3921	97.81	67.45	1431
HSA-MIR-4660	97.79	67.44	1328
HSA-MIR-6879-5P	97.77	65.52	1521
HSA-MIR-342-5P	97.25	64.10	817
HSA-MIR-4653-5P	97.22	67.72	1429
HSA-MIR-6800-5P	94.59	64.80	525
HSA-MIR-1471	77.94	66.74	5

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 74.5% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 7)

• Data demonstrate that the expression of alpha-E-catenin is increased by Sec6 siRNAs, and E-cadherin and beta-catenin localize mainly at the cell-cell contact region in HSC3 cells, which were transfected with Sec6 siRNA. (PMID:22381337)
• Sec6 regulates cytoplasmic translocation of p27 through p27 phosphorylation at Thr157, thereby promoting p27 degradation in the cytoplasm via interaction with Jab1 and Siah1 and suppressing cell cycle progression. (PMID:24949832)
• Sec6 regulates NF-kappaB transcriptional activity via the control of the phosphorylation of IkappaBalpha, p90RSK1, and ERK (PMID:26247921)
• The study explores the role of the exocyst complex component Sec6/8 in genomic stability. (PMID:26283729)
• Sec6 regulate Bcl-2 and Mcl-1 expressions but not Bcl-xl in malignant peripheral nerve sheath tumor cells. (PMID:26892009)
• Sec6 increased the phosphorylation of p38 MAPK through the activation of MAPK kinase 3/6 (MKK3/6). Moreover, Sec6 knockdown suppressed the phosphorylation of HSP27 at Ser(78) and Ser(82) sites via suppression of activated MK2. (PMID:29729335)
• Structural Study of the Exocyst Subunit Human Sec6. (PMID:38007759)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	exoc3	ENSDARG00000014582
mus_musculus	Exoc3	ENSMUSG00000034152
rattus_norvegicus	Ahrr	ENSRNOG00000014721
drosophila_melanogaster	Sec6	FBGN0266671
caenorhabditis_elegans		WBGENE00017284

Paralogs (4): EXOC3L1 (ENSG00000179044), TNFAIP2 (ENSG00000185215), EXOC3L4 (ENSG00000205436), EXOC3L2 (ENSG00000283632)

Protein

Protein identifiers

Exocyst complex component 3 — O60645 (reviewed: O60645)

Alternative names: Exocyst complex component Sec6

All UniProt accessions (4): O60645, D6RB59, D6RBR9, H0Y995

UniProt curated annotations — full annotation on UniProt →

Function. Component of the exocyst complex involved in the docking of exocytic vesicles with fusion sites on the plasma membrane.

Subunit / interactions. The exocyst complex is composed of EXOC1, EXOC2, EXOC3, EXOC4, EXOC5, EXOC6, EXOC7 and EXOC8. Interacts with EXOC3L1. Interacts with BIRC6/bruce. Interacts with MYRIP. Interacts with SLC6A9.

Subcellular location. Cytoplasm. Perinuclear region. Cell projection. Growth cone. Midbody. Golgi apparatus. Neuron projection.

Tissue specificity. Expressed in epididymis (at protein level).

Similarity. Belongs to the SEC6 family.

RefSeq proteins (1): NP_009208* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR010326	EXOC3/Sec6	Family
IPR042532	EXOC3/Sec6_C	Homologous_superfamily

Pfam: PF06046

UniProt features (2 total): chain 1, modified residue 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-O60645-F1	88.79	0.64

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 28

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-1445148	Translocation of SLC2A4 (GLUT4) to the plasma membrane
R-HSA-264876	Insulin processing
R-HSA-5620916	VxPx cargo-targeting to cilium

MSigDB gene sets: 129 (showing top): GOBP_MITOTIC_CYTOKINESIS, GOBP_VESICLE_LOCALIZATION, GOCC_SECRETORY_GRANULE, GOBP_VESICLE_TARGETING, KEGG_TIGHT_JUNCTION, GOBP_VESICLE_MEDIATED_TRANSPORT, REACTOME_MEMBRANE_TRAFFICKING, GOBP_MEMBRANE_DOCKING, GOBP_EXOCYTOSIS, GOBP_VESICLE_DOCKING_INVOLVED_IN_EXOCYTOSIS, WANG_LMO4_TARGETS_DN, GOBP_CYTOKINESIS, GOBP_SECRETION, NIKOLSKY_BREAST_CANCER_5P15_AMPLICON, GOBP_MITOTIC_CELL_CYCLE

GO Biological Process (7): mitotic cytokinesis (GO:0000281), exocytosis (GO:0006887), obsolete vesicle docking involved in exocytosis (GO:0006904), protein transport (GO:0015031), exocyst localization (GO:0051601), membrane fission (GO:0090148), obsolete vesicle tethering involved in exocytosis (GO:0090522)

GO Molecular Function (3): SNARE binding (GO:0000149), cadherin binding (GO:0045296), protein binding (GO:0005515)

GO Cellular Component (11): exocyst (GO:0000145), Golgi apparatus (GO:0005794), cytosol (GO:0005829), growth cone (GO:0030426), midbody (GO:0030496), secretory granule membrane (GO:0030667), perinuclear region of cytoplasm (GO:0048471), cytoplasm (GO:0005737), membrane (GO:0016020), cell projection (GO:0042995), neuron projection (GO:0043005)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Membrane Trafficking	1
Peptide hormone metabolism	1
Cargo trafficking to the periciliary membrane	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	6
cytoplasm	3
mitotic cell cycle	1
cytoskeleton-dependent cytokinesis	1
mitotic cell cycle process	1
vesicle-mediated transport	1
secretion by cell	1
vesicle fusion to plasma membrane	1
transport	1
intracellular protein localization	1
establishment of protein localization	1
protein-containing complex localization	1
membrane organization	1
protein binding	1
cell adhesion molecule binding	1
binding	1
cell cortex	1
vesicle tethering complex	1
endomembrane system	1
intracellular membrane-bounded organelle	1
site of polarized growth	1
distal axon	1
secretory granule	1
cytoplasmic vesicle membrane	1
bounding membrane of organelle	1
intracellular anatomical structure	1
plasma membrane bounded cell projection	1

Protein interactions and networks

STRING

1336 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EXOC3	EXOC2	Q96KP1	999
EXOC3	EXOC4	Q96A65	999
EXOC3	EXOC7	Q9UPT5	999
EXOC3	EXOC8	Q8IYI6	999
EXOC3	EXOC1	Q9NV70	999
EXOC3	EXOC5	O00471	999
EXOC3	EXOC6	Q8TAG9	998
EXOC3	SNAP25	P13795	978
EXOC3	RHOQ	P17081	902
EXOC3	MYRIP	Q8NFW9	900
EXOC3	RAB11A	P24410	868
EXOC3	EXOC6B	Q9Y2D4	769
EXOC3	VPS53	Q5VIR6	749
EXOC3	RALA	P11233	744
EXOC3	COG4	Q9H9E3	717

IntAct

122 interactions, top by confidence:

A	B	Type	Score
EXOC6	EXOC5	psi-mi:“MI:0914”(association)	0.840
EXOC2	EXOC3	psi-mi:“MI:0914”(association)	0.790
EXOC3	EXOC5	psi-mi:“MI:0914”(association)	0.790
EXOC1	EXOC5	psi-mi:“MI:0914”(association)	0.730
EXOC8	EXOC5	psi-mi:“MI:0914”(association)	0.730
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
SDC2	PDPK1	psi-mi:“MI:0914”(association)	0.640
GYPA	TCAF2	psi-mi:“MI:0914”(association)	0.640
EXOC3	PPP1R12C	psi-mi:“MI:0915”(physical association)	0.560
EXOC3	GMCL1	psi-mi:“MI:0915”(physical association)	0.560
FSD2	EXOC3	psi-mi:“MI:0915”(physical association)	0.560
CXCR4	TMEM120B	psi-mi:“MI:0914”(association)	0.530
IL1R2	EXOC5	psi-mi:“MI:0914”(association)	0.530
ILVBL	SLC33A1	psi-mi:“MI:0914”(association)	0.530
LPAR1	TMEM223	psi-mi:“MI:0914”(association)	0.530
EXOC3	TMED1	psi-mi:“MI:0914”(association)	0.510
EXOC4	EXOC5	psi-mi:“MI:0914”(association)	0.510
EXOC5	ZNF609	psi-mi:“MI:0914”(association)	0.510
LAPTM4B	EXOC3	psi-mi:“MI:0915”(physical association)	0.400
EGFR	EXOC3	psi-mi:“MI:0915”(physical association)	0.400
EXOC3	HNRNPA1L2	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (242): EXOC3 (Affinity Capture-MS), EXOC3 (Reconstituted Complex), EXOC3 (Affinity Capture-MS), EXOC3 (Affinity Capture-MS), EXOC3 (Co-fractionation), EXOC3 (Co-fractionation), EXOC3 (Co-fractionation), EXOC4 (Co-fractionation), EXOC6 (Co-fractionation), EXOC7 (Co-fractionation), EXOC8 (Co-fractionation), METAP1 (Co-fractionation), TRMT2A (Co-fractionation), EXOC3 (Affinity Capture-MS), EXOC3 (Proximity Label-MS)

ESM2 similar proteins: A2AV37, A2BID5, A2VDR8, A7E2Y6, A7Z033, B4DZS4, O15068, O35821, O60645, O70576, O94812, P52630, P83436, Q01755, Q03169, Q08CY4, Q0P4Q0, Q0V8C2, Q14746, Q15021, Q17RC7, Q19262, Q1LXZ7, Q2TBH9, Q3T1G7, Q3TBD2, Q3UM29, Q5H9J9, Q5XI00, Q61333, Q62825, Q63406, Q64096, Q6DIA2, Q6GPP1, Q6KAR6, Q7T006, Q80TT2, Q80VA5, Q8K1H7

Diamond homologs: A2AV37, O60645, Q0V8C2, Q0VCR8, Q62825, Q6KAR6, Q86VI1, Q8BI71, Q19262, Q9V8K2, Q2M3D2

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
EXOC3	“form complex”	“Exocyst_EXOC6B variant”	binding
EXOC3	“form complex”	“Exocyst_EXOC6 variant”	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 125 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
VxPx cargo-targeting to cilium	7	45.4×	5e-08
Insulin processing	7	40.0×	7e-08
Translocation of SLC2A4 (GLUT4) to the plasma membrane	9	17.4×	3e-07

GO biological processes:

GO term	Partners	Fold	FDR
obsolete vesicle docking involved in exocytosis	8	49.5×	1e-09
Golgi to plasma membrane transport	7	36.1×	1e-07
membrane fission	8	30.2×	4e-08
mitotic cytokinesis	10	23.8×	3e-09
exocytosis	8	11.1×	7e-05
cell surface receptor signaling pathway	11	6.5×	1e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

128 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	106
Likely benign	3
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

2711 predictions. Top by Δscore:

Variant	Effect	Δscore
5:443287:GAGG:G	donor_gain	1.0000
5:443289:GG:G	donor_gain	1.0000
5:443290:GG:G	donor_gain	1.0000
5:446348:AGGTG:A	donor_loss	1.0000
5:446350:GT:G	donor_loss	1.0000
5:447527:CTTTA:C	acceptor_loss	1.0000
5:447529:TTA:T	acceptor_loss	1.0000
5:447530:TAGG:T	acceptor_loss	1.0000
5:447531:A:AG	acceptor_gain	1.0000
5:447531:A:T	acceptor_loss	1.0000
5:447532:G:GA	acceptor_loss	1.0000
5:447532:G:GG	acceptor_gain	1.0000
5:447532:GGCC:G	acceptor_gain	1.0000
5:447748:CTCAG:C	donor_loss	1.0000
5:447749:TCAG:T	donor_loss	1.0000
5:447750:CAGG:C	donor_loss	1.0000
5:447751:AGG:A	donor_loss	1.0000
5:447752:GGTAC:G	donor_loss	1.0000
5:447753:GTACC:G	donor_loss	1.0000
5:447754:T:A	donor_loss	1.0000
5:453368:A:AG	acceptor_gain	1.0000
5:453369:G:GG	acceptor_gain	1.0000
5:453369:GT:G	acceptor_gain	1.0000
5:456887:A:AG	acceptor_gain	1.0000
5:456888:G:GG	acceptor_gain	1.0000
5:457007:G:GG	donor_gain	1.0000
5:457879:AT:A	acceptor_gain	1.0000
5:457880:T:TA	acceptor_gain	1.0000
5:461956:TCAG:T	acceptor_loss	1.0000
5:461958:A:AG	acceptor_gain	1.0000

AlphaMissense

4939 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:457915:T:A	W394R	1.000
5:457915:T:C	W394R	1.000
5:446338:G:C	A45P	0.999
5:446345:T:C	L47S	0.999
5:447536:G:C	A50P	0.999
5:454029:T:A	W342R	0.999
5:454029:T:C	W342R	0.999
5:457917:G:C	W394C	0.999
5:457917:G:T	W394C	0.999
5:457919:T:C	L395P	0.999
5:457927:G:C	A398P	0.999
5:457951:T:A	W406R	0.999
5:457951:T:C	W406R	0.999
5:457969:C:T	P412S	0.999
5:457970:C:A	P412Q	0.999
5:457970:C:G	P412R	0.999
5:458009:C:G	P425R	0.999
5:458018:T:A	V428D	0.999
5:459360:T:C	M431T	0.999
5:459375:T:C	L436P	0.999
5:462043:C:A	A492D	0.999
5:462053:C:A	N495K	0.999
5:462053:C:G	N495K	0.999
5:462056:C:A	N496K	0.999
5:462056:C:G	N496K	0.999
5:464320:T:A	W562R	0.999
5:464320:T:C	W562R	0.999
5:465806:T:C	L676P	0.999
5:465821:T:C	L681P	0.999
5:466758:C:A	R700S	0.999

dbSNP variants (sampled 300 via entrez): RS1000112045 (5:449230 C>G,T), RS1000319134 (5:464884 G>C), RS1000415538 (5:465161 G>A,C), RS1000457984 (5:445059 G>A), RS1000480847 (5:453220 G>C), RS1000568612 (5:445288 C>T), RS1001048996 (5:456194 T>C), RS1001107799 (5:447667 T>C), RS1001169645 (5:462755 A>G), RS1001258270 (5:460778 G>A), RS1001319335 (5:466172 T>C), RS1001413572 (5:466364 C>A,T), RS1001435610 (5:460573 C>T), RS1001470678 (5:457589 A>G), RS1001569116 (5:446614 C>T)

Disease associations

OMIM: gene MIM:608186 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

7 associations (top):

Study	Trait	p-value
GCST000964_8	Ulcerative colitis	3.000000e-08
GCST002563_7	Hypospadias	9.000000e-09
GCST004615_21	Hemoglobin concentration	5.000000e-09
GCST010083_45	Hemoglobin levels	3.000000e-11
GCST90002383_200	Hematocrit	3.000000e-19
GCST90002384_149	Hemoglobin	1.000000e-17
GCST90002403_438	Red blood cell count	1.000000e-18

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004509	hemoglobin measurement
EFO:0004348	hematocrit
EFO:0004305	erythrocyte count

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL6067025 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

ChEMBL bioactivities

2 potent at pChembl≥5 of 2 total, top 2 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.50	Kd	31.99	nM	CHEMBL5653589
7.50	ED50	31.99	nM	CHEMBL5653589

PubChem BioAssay actives

1 with measured affinity, of 2 total; 1 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2148349: Binding affinity to human EXOC3 incubated for 45 mins by Kinobead based pull down assay	kd	0.0320	uM

CTD chemical–gene interactions

48 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases methylation, decreases expression, affects cotreatment	2
Air Pollutants	affects expression, affects cotreatment, increases abundance, increases oxidation	2
Ozone	affects expression, affects cotreatment, increases oxidation, increases abundance	2
Tretinoin	increases expression	2
bisphenol F	affects cotreatment, decreases expression	1
2,4,6-tribromophenol	decreases expression	1
triphenyl phosphate	affects expression	1
alpha-pinene	affects cotreatment, increases oxidation, increases abundance	1
beta-lapachone	decreases expression, increases expression	1
11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid	affects methylation, increases abundance	1
sodium arsenite	decreases expression	1
tetrabromobisphenol A	decreases expression	1
methacrylaldehyde	increases oxidation, increases abundance, affects cotreatment	1
tamibarotene	affects expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
bisphenol S	affects cotreatment, decreases expression	1
NSC 689534	affects binding, increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Acrolein	affects cotreatment, increases oxidation, increases abundance	1
Ethanol	affects cotreatment, increases abundance, increases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	decreases methylation, increases methylation	1
Cadmium	increases expression	1
Caffeine	decreases phosphorylation	1
Cannabinoids	affects methylation, increases abundance	1
Cisplatin	affects cotreatment, increases expression	1
Copper	affects binding, increases expression	1
Dexamethasone	affects cotreatment, decreases expression	1

ChEMBL screening assays

1 unique, capped per target: 1 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5651391	Binding	Binding affinity to human EXOC3 incubated for 45 mins by Kinobead based pull down assay	NVP-BHG712: Effects of Regioisomers on the Affinity and Selectivity toward the EPHrin Family. — ChemMedChem

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.